Cardio Diagnostics to Present AI Cardiovascular Risk Tools at Benefits Conferences, Targeting Employer Health Plans
Cardio Diagnostics Holdings will showcase its AI-powered cardiovascular risk assessments at four national benefits conferences in June, aiming to help employers and plan administrators reduce healthcare costs and improve workforce productivity by identifying at-risk individuals earlier.
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) announced it will exhibit at four national benefits conferences in June to engage employers, brokers, union trustees and plan administrators on strategies to address cardiovascular disease, a leading driver of health plan costs and workforce productivity losses. The company will showcase its AI-powered cardiovascular risk assessment offerings, including Epi+Gen CHD, PrecisionCHD and the HeartRisk population insights platform, designed to identify at-risk individuals earlier and help benefits decision-makers better manage healthcare costs and outcomes.
Cardiovascular disease remains the leading cause of death globally and a significant burden on employers. According to the Centers for Disease Control and Prevention, heart disease costs the United States about $363 billion each year in health care services, medications, and lost productivity. By targeting early detection, Cardio Diagnostics' solutions aim to reduce these expenses while improving employee health outcomes. The company's technology leverages a proprietary AI-driven Integrated Genetic-Epigenetic Engine to provide personalized risk assessments that go beyond traditional methods.
The conferences provide a platform for the company to connect with key stakeholders in employee benefits. Brokers and plan administrators are increasingly seeking innovative tools to manage chronic disease risks and contain costs. Cardio Diagnostics' offerings could enable more precise targeting of preventive care resources, potentially reducing the incidence of heart attacks and strokes among employees. This proactive approach aligns with broader trends in value-based care and population health management.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease.
For more details on the press release, visit https://ibn.fm/qFRHu. The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO.